Rxcurve
HCPCS J0737 · per 300 MG

Inj, clindamycin (baxter)

Products billed under this code include Clindamycin Phosphate.

Payment limit per 300 MG, by effective quarter, 4Q23 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.

Products billed under J0737

From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.

ProductLabelerNDCUnits / pkgLimit / pkg
Clindamycin Phosphate Baxter Healthcare Corporation 00338-9545-24 24 $49.632
Clindamycin Phosphate Baxter Healthcare Corporation 00338-9549-24 48 $99.264
Clindamycin Phosphate Baxter Healthcare Corporation 00338-9553-24 72 $148.896

Every quarter

QuarterPayment limitChangeBilling unitDescriptionSource file
4Q26 $2.068 −$0.118 300 MG Inj, clindamycin (baxter) v1, posted September 17, 2026
3Q26 $2.186 −$0.138 300 MG Inj, clindamycin (baxter) v1, posted September 15, 2026
2Q26 $2.324 −$0.022 300 MG Inj, clindamycin (baxter) v1, posted September 15, 2026
1Q26 $2.346 +$0.138 300 MG Inj, clindamycin (baxter) v1, posted September 15, 2026
4Q25 $2.208 +$0.491 300 MG Inj, clindamycin (baxter) v1, posted September 8, 2026
3Q25 $1.717 −$0.81 300 MG Inj, clindamycin (baxter) v1, posted March 10, 2026
2Q25 $2.527 −$0.078 300 MG Inj, clindamycin (baxter) v1, posted March 10, 2026
1Q25 $2.605 −$0.21 300 MG Inj, clindamycin (baxter) v1, posted December 19, 2025
4Q24 $2.815 −$0.449 300 MG Inj, clindamycin (baxter) v1, posted June 11, 2025
3Q24 $3.264 +$1.057 300 MG Inj, clindamycin (baxter) v1, posted June 11, 2025
2Q24 $2.207 +$0.456 300 MG Inj, clindamycin (baxter) v1, posted March 11, 2025
1Q24 $1.751 −$0.843 300 MG Inj, clindamycin (baxter) v1, posted December 19, 2024
4Q23 $2.594 – 300 MG Inj, clindamycin (baxter) v1, posted October 10, 2024

“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.

CMS source files